Last reviewed · How we verify
NCT06845033: LEAP2fMRI
Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity
NA trial testing LEAP2 infusion in Obesity and Overweight in 28 participants. Not yet recruiting.
1 November 2026
Quick facts
| Lead sponsor | University Hospital, Gentofte, Copenhagen |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 28 |
| Start date | 1 May 2025 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2027 |
Drugs / interventions tested
- LEAP2 infusion
- Placebo
Conditions studied
- Obesity and Overweight — all drugs for Obesity and Overweight →
Sponsor
University Hospital, Gentofte, Copenhagen
Who can join
Adults 18 to 60, male only, with Obesity and Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The naturally occurring peptide hormone liver-expressed antimicrobial peptide 2 (LEAP2) in an antagonist/inverse agonist towards the ghrelin receptor. Ghrelin administration has previously been shown to increase food cue reactivity in brain regions related to appetite and reward using functional MRI scans. The aim of this clinical study is to investigate the effects of LEAP2 infusion on food cue reactivity in brain regions related to appetite and reward. Since LEAP2 is an antagonist/inverse agonist towards the ghrelin receptor we hypothesize, that LEAP2 infusion will decrease food cue reactivity in the above-mentioned regions compared to placebo infusion. Participants with obesity (BMI 30-50 kg/m2) will be included and complete two experimental days with either LEAP2 or placebo infusion in a randomized crossover manner. On experimental days, participants will undergo a MRI scan with functional and anatomical modalities. The study will attribute to gain a deeper understanding of the ghrelin system and its interaction with appetite regulation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06845033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity and Overweight
Currently open trials in the same condition.
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07032545 — Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors · NA · recruiting
- NCT06768827 — New Mechanisms of Obesity · NA · recruiting
- NCT06935838 — Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV · Phase 2 · recruiting
Other University Hospital, Gentofte, Copenhagen trials
Trials by the same sponsor.
- NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
- NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
- NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
- NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed
- NCT06895408 — Separate and Combined Extrapancreatic Effects of GIP and GLP-1 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06845033 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06845033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing